Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable low-field magnetic resonance imaging, which could provide a significant advancement in medical imaging by reducing the cost and improving the accessibility of MRI. This research reinforces the significance of the clinical and commercial opportunity for Imagion’s nanoparticles.
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
September 19, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it